Abstract
A group of 12 children with advanced neuroblastoma (7 Stage IV and 5 Stage III), selected by their initial response to chemotherapy with pulsed cyclophosphamide/vincristine/Adriamycin (CVA), were given consolidation therapy with high-dose melphalan (140 mg/m2) and then surgical removal of residual disease. Twenty-two high-dose melphalan procedures were combined with autologous marrow grafting to offset myelotoxicity and were well tolerated. In each of 2 additional children, procedures carried out without marrow autografting led to serious marrow and mucosal toxicity. There were no treatment-related deaths. In 7/11 patients with evaluable computerized tomographic (CT) scans there was a decrease in maximum diameter of the primary tumour after melphalan. Complete response was achieved in 6 patients, of whom 3 are well and have no evidence of disease at 35, 33 and 18 months from completion of all treatment, however, although survival (median 23 months) of all 12 autografted patients is longer than that of 28 comparable children treated between 1970-77 with conventional chemotherapy (median 14 months) the difference is not statistically significant. High-dose melphalan is a safe and tolerable treatment in children when combined with autologous marrow grafting, but further study is required to determine whether the procedure can improve prognosis for patients with advanced neuroblastoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Pritchard, J., McElwain, T. & Graham-Pole, J. High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma. Br J Cancer 45, 86–94 (1982). https://doi.org/10.1038/bjc.1982.11
Issue Date:
DOI: https://doi.org/10.1038/bjc.1982.11
This article is cited by
-
Not too little, not too much—just right! (Better ways to give high dose melphalan)
Bone Marrow Transplantation (2014)
-
Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: purging efficacy, hematopoietic reconstitution and long-term outcome in children with high-risk neuroblastoma
Bone Marrow Transplantation (2002)
-
Complete surgical resection combined with aggressive adjuvant chemotherapy and bone marrow transplantation prolongs survival in children with advanced neuroblastoma
Annals of Surgical Oncology (1995)
-
The effect ofl-amino acid oxidase on activity of melphalan against an intracranial xenograft
Cancer Chemotherapy and Pharmacology (1995)
-
Hematopoietic reconstitution after high-dose chemotherapy and autologous nonfrozen bone marrow rescue
Annals of Hematology (1991)